Executive editors Michael Flanagan and Simon King discuss Valeant's announcement that CEO Michael Pearson is to be replaced and whether this will put the company on a firmer footing in light of recent challenges.
To read more The First Take articles, click here.
About FirstWord Pharma | Upgrade Your FirstWord Pharma | Contact FirstWord Pharma | FirstWord Reports
Advertise with FirstWord Pharma | Industry Partner Showcase
All Contents Copyright © 2021 Doctor's Guide Publishing Limited. All Rights Reserved.
Terms of Use | Privacy Policy